Advertisement

Journal of Neuro-Oncology

, Volume 125, Issue 3, pp 551–583 | Cite as

The role of radiotherapy in the management of patients with diffuse low grade glioma

A systematic review and evidence-based clinical practice guideline
  • Timothy C. Ryken
  • Ian Parney
  • John Buatti
  • Steven N. Kalkanis
  • Jeffrey J. Olson
Topic Review & Clinical Guidelines

Abstract

Questions

  1. 1.

    What is the optimal role of external beam radiotherapy in the management of adult patients with newly diagnosed low-grade glioma (LGG) in terms of improving outcome (i.e. survival, complications, seizure control or other reported outcomes of interest)?

     
  2. 2.

    Which radiation strategies (dose, timing, fractionation, stereotactic radiation, brachytherapy, chemotherapy) improve outcomes compared to standard external beam radiation therapy in the initial management of low grade gliomas in adults?

     
  3. 3.

    Do specific factors (e.g. age, volume, extent of resection, genetic subtype) identify subgroups with better outcomes following radiation therapy than the general population of adults with newly diagnosed low-grade gliomas?

     

Target population

These recommendations apply to adults with newly diagnosed diffuse LGG.

Recommendations

Outcomes in adult patients with newly diagnosed low grade glioma treated with radiotherapy

Level I Radiotherapy is recommended in the management of newly diagnosed low-grade glioma in adults to prolong progression free survival, irrespective of extent of resection.

Level II Radiotherapy is recommended in the management of newly diagnosed low grade glioma in adults as an equivalent alternative to observation in preserving cognitive function, irrespective of extent of resection.

Level III Radiotherapy is recommended in the management of newly diagnosed low grade glioma in adults to improve seizure control in patients with epilepsy and subtotal resection.

Level III Radiotherapy is recommended in the management of newly diagnosed low-grade glioma in adults to prolong overall survival in patients with subtotal resection.

Level III Consideration of the risk of radiation induced morbidity, including cognitive decline, imaging abnormalities, metabolic dysfunction and malignant transformation, is recommended when the delivery of radiotherapy is selected in the management of newly diagnosed low-grade glioma in adults.

Strategies of radiotherapy in adult patients with newly diagnosed low grade glioma

Level I Lower dose radiotherapy is recommended as an equivalent alternative to higher dose immediate postoperative radiotherapy (45–50.4 vs. 59.4–64.8 Gy) in the management of newly diagnosed low-grade glioma in adults with reduced toxicity.

Level III Delaying radiotherapy until recurrence or progression is recommended as an equivalent alternative to immediate postoperative radiotherapy in the management of newly diagnosed low-grade glioma in adults but may result in shorter time to progression.

Level III The addition of chemotherapy to radiotherapy is not recommended over whole brain radiotherapy alone in the management of low-grade glioma, as it provides no additional survival benefit.

Level III Limited-field radiotherapy is recommended over whole brain radiotherapy in the management of low-grade glioma.

Level III Either stereotactic radiosurgery or brachytherapy are recommended as acceptable alternatives to external radiotherapy in selected patients.

Prognostic factors in adult patients with newly diagnosed low grade glioma treated with radiotherapy

Level II It is recommended that age greater than 40 years, astrocytic pathology, diameter greater than 6 cm, tumor crossing the midline and preoperative neurological deficit be considered as negative prognostic indicators when predicting overall survival in adult low grade glioma patients treated with radiotherapy.

Level II It is recommended that smaller tumor size, extent of surgical resection and higher mini-mental status exam be considered as positive prognostic indicators when predicting overall survival and progression free survival in patients in adult low grade glioma patients treated with radiotherapy.

Level III It is recommended that seizures at presentation, presence of oligodendroglial histological component and 1p19q deletion (along with additional relevant factors—see Table 1) be considered as positive prognostic indicators when predicting response to radiotherapy in adults with low grade gliomas.

Level III It is recommended that increasing age, decreasing performance status, decreasing cognition, presence of astrocytic histological component (along with additional relevant factors (see Tables 1, 2) be considered as negative prognostic indicators when predicting response to radiotherapy.

Keywords

Low grade glioma Astrocytoma Oligodendroglioma Radiation Radiation sensitizer Systematic review Practice guideline 

Notes

Acknowledgments

We acknowledge the significant contributions of Laura Mitchell, Senior Manager of Clinical Practice Guidelines for the CNS, the AANS/CNS Joint Guidelines Committee (JGC) for their review, comments and suggestions, and Anne Woznica and Mary Bodach for their assistance with the literature searches. We also acknowledge the following individual JGC members for their contributions throughout the review process: Kevin Cockroft, MD, Sepideh Amin-Hanjani, MD, Kimon Bekelis, MD, Isabelle Germano, MD, Daniel Hoh, MD, Steven Hwang, MD, Cheerag Dipakkumar Upadhyaya, MD, Christopher Winfree, MD, and Brad Zacharia, MD.

Disclosures

Dr. Parney is a consultant for Agenus, Inc. Dr. Kalkanis is a consultant for Arbor and Varian. Dr. Olson is a consultant for the American Cancer Society; has received research funding from the National Cancer Institute, Genentech, and Millennium; and has received investigational drug provision from Merck.

References

  1. 1.
    Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O, Darcel F, Stenning S, Pierart M, Van Glabbeke M (2002) Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 52:316–324PubMedCrossRefGoogle Scholar
  2. 2.
    Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, Mascarenhas F, Horiot JC, Parvinen LM, van Reijn M, Jager JJ, Fabrini MG, van Alphen AM, Hamers HP, Gaspar L, Noordman E, Pierart M, van Glabbeke M (1996) A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) study 22844. Int J Radiat Oncol Biol Phys 36:549–556PubMedCrossRefGoogle Scholar
  3. 3.
    Kiebert GM, Curran D, Aaronson NK, Bolla M, Menten J, Rutten EH, Nordman E, Silvestre ME, Pierart M, Karim AB (1998) Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer 34:1902–1909PubMedCrossRefGoogle Scholar
  4. 4.
    Shaw E, Arusell R, Scheithauer B, O’Fallon J, O’Neill B, Dinapoli R, Nelson D, Earle J, Jones C, Cascino T, Nichols D, Ivnik R, Hellman R, Curran W, Abrams R (2002) Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 20:2267–2276PubMedCrossRefGoogle Scholar
  5. 5.
    Brown PD, Buckner JC, O’Fallon JR, Iturria NL, Brown CA, O’Neill BP, Scheithauer BW, Dinapoli RP, Arusell RM, Curran WJ, Abrams R, Shaw EG (2003) Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. J Clin Oncol 21:2519–2524. doi: 10.1200/jco.2003.04.172 PubMedCrossRefGoogle Scholar
  6. 6.
    Klein M, Heimans JJ, Aaronson NK, van der Ploeg HM, Grit J, Muller M, Postma TJ, Mooij JJ, Boerman RH, Beute GN, Ossenkoppele GJ, van Imhoff GW, Dekker AW, Jolles J, Slotman BJ, Struikmans H, Taphoorn MJ (2002) Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 360:1361–1368PubMedCrossRefGoogle Scholar
  7. 7.
    Postma TJ, Klein M, Verstappen CC, Bromberg JE, Swennen M, Langendijk JA, Taphoorn MJ, Scheltens P, Slotman BJ, van der Ploeg HM, Aaronson NK, Heimans JJ (2002) Radiotherapy-induced cerebral abnormalities in patients with low-grade glioma. Neurology 59:121–123PubMedCrossRefGoogle Scholar
  8. 8.
    Surma-aho O, Niemela M, Vilkki J, Kouri M, Brander A, Salonen O, Paetau A, Kallio M, Pyykkonen J, Jaaskelainen J (2001) Adverse long-term effects of brain radiotherapy in adult low-grade glioma patients. Neurology 56:1285–1290PubMedCrossRefGoogle Scholar
  9. 9.
    Swennen MH, Bromberg JE, Witkamp TD, Terhaard CH, Postma TJ, Taphoorn MJ (2004) Delayed radiation toxicity after focal or whole brain radiotherapy for low-grade glioma. J Neurooncol 66:333–339PubMedCrossRefGoogle Scholar
  10. 10.
    Taphoorn MJ, Schiphorst AK, Snoek FJ, Lindeboom J, Wolbers JG, Karim AB, Huijgens PC, Heimans JJ (1994) Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy. Ann Neurol 36:48–54. doi: 10.1002/ana.410360111 PubMedCrossRefGoogle Scholar
  11. 11.
    Taphoorn MJ, Heimans JJ, van der Veen EA, Karim AB (1995) Endocrine functions in long-term survivors of low-grade supratentorial glioma treated with radiation therapy. J Neurooncol 25:97–102PubMedCrossRefGoogle Scholar
  12. 12.
    van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmstrom PO, Collette L, Pierart M, Mirimanoff R, Karim AB (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985–990PubMedCrossRefGoogle Scholar
  13. 13.
    Grabenbauer GG, Roedel CM, Paulus W, Ganslandt O, Schuchardt U, Buchfelder M, Schrell U, Fahlbusch R, Huk WJ, Sauer R (2000) Supratentorial low-grade glioma: results and prognostic factors following postoperative radiotherapy. Strahlenther Onkol 176:259–264PubMedCrossRefGoogle Scholar
  14. 14.
    Hanzely Z, Polgar C, Fodor J, Brucher JM, Vitanovics D, Mangel LC, Afra D (2003) Role of early radiotherapy in the treatment of supratentorial WHO Grade II astrocytomas: long-term results of 97 patients. J Neurooncol 63:305–312PubMedCrossRefGoogle Scholar
  15. 15.
    Hasegawa A, Mizoe JE, Tsujii H, Kamada T, Jingu K, Iwadate Y, Nakazato Y, Matsutani M, Takakura K (2012) Experience with carbon ion radiotherapy for WHO Grade 2 diffuse astrocytomas. Int J Radiat Oncol Biol Phys 83:100–106. doi: 10.1016/j.ijrobp.2011.06.1952 PubMedCrossRefGoogle Scholar
  16. 16.
    Henderson MA, Fakiris AJ, Timmerman RD, Worth RM, Lo SS, Witt TC (2009) Gamma knife stereotactic radiosurgery for low-grade astrocytomas. Stereotact Funct Neurosurg 87:161–167. doi: 10.1159/000209297 PubMedCrossRefGoogle Scholar
  17. 17.
    Jeremic B, Milicic B, Grujicic D, Samardzic M, Antunovic V, Dagovic A, Aleksandrovic J, Stojanovic M (2003) Hyperfractionated radiation therapy for incompletely resected supratentorial low-grade glioma: a 10-year update of a phase II study. Int J Radiat Oncol Biol Phys 57:465–471PubMedCrossRefGoogle Scholar
  18. 18.
    Jeremic B, Shibamoto Y, Grujicic D, Milicic B, Stojanovic M, Nikolic N, Dagovic A (1998) Hyperfractionated radiation therapy for incompletely resected supratentorial low-grade glioma. A phase II study. Radiother Oncol 49:49–54PubMedCrossRefGoogle Scholar
  19. 19.
    Mansur DB, Hekmatpanah J, Wollman R, Macdonald L, Nicholas K, Beckmann E, Mundt AJ (2000) Low grade gliomas treated with adjuvant radiation therapy in the modern imaging era. Am J Clin Oncol 23:222–226PubMedCrossRefGoogle Scholar
  20. 20.
    Mehrkens JH, Kreth FW, Muacevic A, Ostertag CB (2004) Long term course of WHO grade II astrocytomas of the Insula of Reil after I-125 interstitial irradiation. J Neurol 251:1455–1464. doi: 10.1007/s00415-004-0561-6 PubMedCrossRefGoogle Scholar
  21. 21.
    Nakamura M, Konishi N, Tsunoda S, Nakase H, Tsuzuki T, Aoki H, Sakitani H, Inui T, Sakaki T (2000) Analysis of prognostic and survival factors related to treatment of low-grade astrocytomas in adults. Oncology 58:108–116. doi: 10.1159/000012087 PubMedCrossRefGoogle Scholar
  22. 22.
    Olson JD, Riedel E, DeAngelis LM (2000) Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology 54:1442–1448PubMedCrossRefGoogle Scholar
  23. 23.
    Roberge D, Souhami L, Olivier A, Leblanc R, Podgorsak E (2006) Hypofractionated stereotactic radiotherapy for low grade glioma at McGill University: long-term follow-up. Technol Cancer Res Treat 5:1–8PubMedCrossRefGoogle Scholar
  24. 24.
    Schomas DA, Laack NN, Brown PD (2009) Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer 115:3969–3978. doi: 10.1002/cncr.24444 PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    van Kampen M, Engenhart-Cabillic R, Debus J, Hess T, Schad LR, Wannenmacher MF (1996) Low-grade astrocytoma: treatment with conventionally fractionated stereotactic radiation therapy. Radiology 201:275–278. doi: 10.1148/radiology.201.1.8816559 PubMedCrossRefGoogle Scholar
  26. 26.
    Yeh SA, Lee TC, Chen HJ, Lui CC, Sun LM, Wang CJ, Huang EY (2002) Treatment outcomes and prognostic factors of patients with supratentorial low-grade oligodendroglioma. Int J Radiat Oncol Biol Phys 54:1405–1409PubMedCrossRefGoogle Scholar
  27. 27.
    Lunsford LD, Somaza S, Kondziolka D, Flickinger JC (1995) Survival after stereotactic biopsy and irradiation of cerebral nonanaplastic, nonpilocytic astrocytoma. J Neurosurg 82:523–529. doi: 10.3171/jns.1995.82.4.0523 PubMedCrossRefGoogle Scholar
  28. 28.
    Bauman G, Lote K, Larson D, Stalpers L, Leighton C, Fisher B, Wara W, MacDonald D, Stitt L, Cairncross JG (1999) Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 45:923–929PubMedCrossRefGoogle Scholar
  29. 29.
    North CA, North RB, Epstein JA, Piantadosi S, Wharam MD (1990) Low-grade cerebral astrocytomas. Survival and quality of life after radiation therapy. Cancer 66:6–14PubMedCrossRefGoogle Scholar
  30. 30.
    Park KJ, Kano H, Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD (2011) Early or delayed radiosurgery for WHO grade II astrocytomas. J Neurooncol 103:523–532. doi: 10.1007/s11060-010-0409-0 PubMedCrossRefGoogle Scholar
  31. 31.
    Schnell O, Scholler K, Ruge M, Siefert A, Tonn JC, Kreth FW (2008) Surgical resection plus stereotactic 125I brachytherapy in adult patients with eloquently located supratentorial WHO grade II glioma—feasibility and outcome of a combined local treatment concept. J Neurol 255:1495–1502. doi: 10.1007/s00415-008-0948-x PubMedCrossRefGoogle Scholar
  32. 32.
    Suchorska B, Ruge M, Treuer H, Sturm V, Voges J (2011) Stereotactic brachytherapy of low-grade cerebral glioma after tumor resection. Neuro Oncol 13:1133–1142. doi: 10.1093/neuonc/nor100 PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Wang LW, Shiau CY, Chung WY, Wu HM, Guo WY, Liu KD, Ho DM, Wong TT, Pan DH (2006) Gamma Knife surgery for low-grade astrocytomas: evaluation of long-term outcome based on a 10-year experience. J Neurosurg 105(Suppl):127–132. doi: 10.3171/sup.2006.105.7.127 Google Scholar
  34. 34.
    Youland RS, Brown PD, Giannini C, Parney IF, Uhm JH, Laack NN (2012) Adult low-grade glioma: 19-year experience at a single institution. Am J Clin Oncol. doi: 10.1097/COC.0b013e31825d580a Google Scholar
  35. 35.
    Schomas DA, Laack NN, Rao RD, Meyer FB, Shaw EG, O’Neill BP, Giannini C, Brown PD (2009) Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro Oncol 11:437–445. doi: 10.1215/15228517-2008-102 PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Barcia JA, Barcia-Salorio JL, Ferrer C, Ferrer E, Algas R, Hernandez G (1994) Stereotactic radiosurgery of deeply seated low grade gliomas. Acta Neurochir Suppl 62:58–61PubMedCrossRefGoogle Scholar
  37. 37.
    Scerrati M, Montemaggi P, Iacoangeli M, Roselli R, Rossi GF (1994) Interstitial brachytherapy for low-grade cerebral gliomas: analysis of results in a series of 36 cases. Acta Neurochir (Wien) 131:97–105CrossRefGoogle Scholar
  38. 38.
    Schatz CR, Kreth FW, Faist M, Warnke PC, Volk B, Ostertag CB (1994) Interstitial 125-iodine radiosurgery of low-grade gliomas of the insula of Reil. Acta Neurochir (Wien) 130:80–89CrossRefGoogle Scholar
  39. 39.
    Kahlenberg CA, Fadul CE, Roberts DW, Thadani VM, Bujarski KA, Scott RC, Jobst BC (2012) Seizure prognosis of patients with low-grade tumors. Seizure 21:540–545. doi: 10.1016/j.seizure.2012.05.014 PubMedCrossRefGoogle Scholar
  40. 40.
    Rogers LR, Morris HH, Lupica K (1993) Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy. Neurology 43:1599–1601PubMedCrossRefGoogle Scholar
  41. 41.
    Shankar A, Rajshekhar V (2003) Radiological and clinical outcome following stereotactic biopsy and radiotherapy for low-grade insular astrocytomas. Neurol India 51:503–506PubMedGoogle Scholar
  42. 42.
    Taillandier L, Duffau H (2009) Epilepsy and insular Grade II gliomas: an interdisciplinary point of view from a retrospective monocentric series of 46 cases. Neurosurg Focus 27:E8. doi: 10.3171/2009.6.focus09102 PubMedCrossRefGoogle Scholar
  43. 43.
    Warnke PC, Berlis A, Weyerbrock A, Ostertag CB (1997) Significant reduction of seizure incidence and increase of benzodiazepine receptor density after interstitial radiosurgery in low-grade gliomas. Acta Neurochir Suppl 68:90–92PubMedGoogle Scholar
  44. 44.
    Correa DD, DeAngelis LM, Shi W, Thaler HT, Lin M, Abrey LE (2007) Cognitive functions in low-grade gliomas: disease and treatment effects. J Neurooncol 81:175–184. doi: 10.1007/s11060-006-9212-3 PubMedCrossRefGoogle Scholar
  45. 45.
    Correa DD, Shi W, Thaler HT, Cheung AM, DeAngelis LM, Abrey LE (2008) Longitudinal cognitive follow-up in low grade gliomas. J Neurooncol 86:321–327. doi: 10.1007/s11060-007-9474-4 PubMedCrossRefGoogle Scholar
  46. 46.
    Douw L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, Postma TJ, Vandertop WP, Mooij JJ, Boerman RH, Beute GN, Sluimer JD, Slotman BJ, Reijneveld JC, Heimans JJ (2009) Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 8:810–818. doi: 10.1016/s1474-4422(09)70204-2 PubMedCrossRefGoogle Scholar
  47. 47.
    Gondi V, Hermann BP, Mehta MP, Tome WA (2012) Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys 83:e487–e493. doi: 10.1016/j.ijrobp.2011.10.021 PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Jalali R, Mallick I, Dutta D, Goswami S, Gupta T, Munshi A, Deshpande D, Sarin R (2010) Factors influencing neurocognitive outcomes in young patients with benign and low-grade brain tumors treated with stereotactic conformal radiotherapy. Int J Radiat Oncol Biol Phys 77:974–979. doi: 10.1016/j.ijrobp.2009.06.025 PubMedCrossRefGoogle Scholar
  49. 49.
    Kamasak K, Ekici MA, Gocmez C, Tucer B, Basarslan SK, Kurtsoy A (2012) Malign transformation in the low grade astrocytomas and related factors. Turk Neurosurg 22:566–575. doi: 10.5137/1019-5149.jtn.5347-11.3 PubMedGoogle Scholar
  50. 50.
    Kandil A, Khafaga Y, ElHusseiny G, Allam A, Jamshed A, Schultz H (1999) Low-grade astrocytoma–a retrospective analysis of 102 patients. Acta Oncol 38:1051–1056PubMedCrossRefGoogle Scholar
  51. 51.
    Steiger HJ, Markwalder RV, Seiler RW, Ebeling U, Reulen HJ (1990) Early prognosis of supratentorial grade 2 astrocytomas in adult patients after resection or stereotactic biopsy. An analysis of 50 cases operated on between 1984 and 1988. Acta Neurochir (Wien) 106:99–105CrossRefGoogle Scholar
  52. 52.
    Laack NN, Brown PD, Ivnik RJ, Furth AF, Ballman KV, Hammack JE, Arusell RM, Shaw EG, Buckner JC (2005) Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study. Int J Radiat Oncol Biol Phys 63:1175–1183. doi: 10.1016/j.ijrobp.2005.04.016 PubMedCrossRefGoogle Scholar
  53. 53.
    Brown PD, Buckner JC, O’Fallon JR, Iturria NL, O’Neill BP, Brown CA, Scheithauer BW, Dinapoli RP, Arusell RM, Curran WJ, Abrams R, Shaw EG (2004) Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma. Int J Radiat Oncol Biol Phys 59:117–125. doi: 10.1016/j.ijrobp.2003.10.040 PubMedCrossRefGoogle Scholar
  54. 54.
    Kida Y, Kobayashi T, Mori Y (2000) Gamma knife radiosurgery for low-grade astrocytomas: results of long-term follow up. J Neurosurg 93(Suppl 3):42–46. doi: 10.3171/jns.2000.93.supplement3.0042 PubMedGoogle Scholar
  55. 55.
    Hadjipanayis CG, Niranjan A, Tyler-Kabara E, Kondziolka D, Flickinger JC, Lunsford LD (2002) Stereotactic radiosurgery for well-circumscribed fibrillary grade II astrocytomas: an initial experience. Stereotact Funct Neurosurg 79:13–24. doi: 10.1159/000069500 PubMedCrossRefGoogle Scholar
  56. 56.
    Combs SE, Schulz-Ertner D, Thilmann C, Edler L, Debus J (2005) Fractionated stereotactic radiation therapy in the management of primary oligodendroglioma and oligoastrocytoma. Int J Radiat Oncol Biol Phys 62:797–802. doi: 10.1016/j.ijrobp.2004.11.011 PubMedCrossRefGoogle Scholar
  57. 57.
    Kreth FW, Faist M, Rossner R, Volk B, Ostertag CB (1997) Supratentorial World Health Organization Grade 2 astrocytomas and oligoastrocytomas. A new pattern of prognostic factors. Cancer 79:370–379PubMedCrossRefGoogle Scholar
  58. 58.
    Kreth FW, Faist M, Grau S, Ostertag CB (2006) Interstitial 125I radiosurgery of supratentorial de novo WHO Grade 2 astrocytoma and oligoastrocytoma in adults: long-term results and prognostic factors. Cancer 106:1372–1381. doi: 10.1002/cncr.21750 PubMedCrossRefGoogle Scholar
  59. 59.
    Daniels TB, Brown PD, Felten SJ, Wu W, Buckner JC, Arusell RM, Curran WJ, Abrams RA, Schiff D, Shaw EG (2011) Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys 81:218–224. doi: 10.1016/j.ijrobp.2010.05.003 PubMedCentralPubMedCrossRefGoogle Scholar
  60. 60.
    Leighton C, Fisher B, Macdonald D, Stitt L, Bauman G, Cairncross J (2007) The dose-volume interaction in adult supratentorial low-grade glioma: higher radiation dose is beneficial among patients with partial resection. J Neurooncol 82:165–170. doi: 10.1007/s11060-006-9141-1 PubMedCrossRefGoogle Scholar
  61. 61.
    Knisely JP, Haffty BG, Christopher SR (1997) Early vs. delayed radiotherapy in a small cohort of patients with supratentorial low grade glioma. J Neurooncol 34:23–29PubMedCrossRefGoogle Scholar
  62. 62.
    Leighton C, Fisher B, Bauman G, Depiero S, Stitt L, MacDonald D, Cairncross G (1997) Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 15:1294–1301PubMedGoogle Scholar
  63. 63.
    Eyre HJ, Crowley JJ, Townsend JJ, Eltringham JR, Morantz RA, Schulman SF, Quagliana JM, Al-Sarraf M (1993) A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg 78:909–914. doi: 10.3171/jns.1993.78.6.0909 PubMedCrossRefGoogle Scholar
  64. 64.
    Lo SS, Cho KH, Hall WA, Hernandez WL, Kossow RJ, Lee CK, Clark HB (2001) Does the extent of surgery have an impact on the survival of patients who receive postoperative radiation therapy for supratentorial low-grade gliomas? Int J Cancer 96(Suppl):71–78. doi: 10.1002/ijc.10359 PubMedCrossRefGoogle Scholar
  65. 65.
    Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076–2084PubMedCrossRefGoogle Scholar
  66. 66.
    Shaw E, Bernstein M, Recht L (1998) Practice parameters in adults with suspected or known supratentorial nonoptic pathway low-grade glioma. Neurosurg Focus 4:e10. doi: 10.3171/foc.1998.4.1.11 Google Scholar
  67. 67.
    Berger MS, Deliganis AV, Dobbins J, Keles GE (1994) The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74:1784–1791PubMedCrossRefGoogle Scholar
  68. 68.
    Buatti JM, Meeks SL, Ryken TC, Carlisle TL (2002) Low-grade gliomas: answering one question in a myriad of new questions. J Clin Oncol 20:2223–2224PubMedGoogle Scholar
  69. 69.
    Bauman G, Fisher B, Watling C, Cairncross JG, Macdonald D (2009) Adult supratentorial low-grade glioma: long-term experience at a single institution. Int J Radiat Oncol Biol Phys 75:1401–1407. doi: 10.1016/j.ijrobp.2009.01.010 PubMedCrossRefGoogle Scholar
  70. 70.
    Lote K, Egeland T, Hager B, Stenwig B, Skullerud K, Berg-Johnsen J, Storm-Mathisen I, Hirschberg H (1997) Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J Clin Oncol 15:3129–3140PubMedGoogle Scholar
  71. 71.
    Scerrati M, Roselli R, Iacoangeli M, Pompucci A, Rossi GF (1996) Prognostic factors in low grade (WHO grade II) gliomas of the cerebral hemispheres: the role of surgery. J Neurol Neurosurg Psychiatry 61:291–296PubMedCentralPubMedCrossRefGoogle Scholar
  72. 72.
    Touboul E, Schlienger M, Buffat L, Balosso J, Minne JF, Schwartz LH, Pene F, Masri-Zada T, Lot G, Devaux B (1995) Radiation therapy with or without surgery in the management of low-grade brain astrocytomas. A retrospective study of 120 patients. Bull du Cancer Radiother 82:388–395CrossRefGoogle Scholar
  73. 73.
    Janny P, Cure H, Mohr M, Heldt N, Kwiatkowski F, Lemaire JJ, Plagne R, Rozan R (1994) Low grade supratentorial astrocytomas. Management and prognostic factors. Cancer 73:1937–1945PubMedCrossRefGoogle Scholar
  74. 74.
    Reichenthal E, Feldman Z, Cohen ML, Loven D, Zucker G (1992) Hemispheric supratentorial low-grade astrocytoma. Neurochirurgia 35:18–22. doi: 10.1055/s-2008-1052239 PubMedGoogle Scholar
  75. 75.
    Claus EB, Black PM (2006) Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001. Cancer 106:1358–1363. doi: 10.1002/cncr.21733 PubMedCrossRefGoogle Scholar
  76. 76.
    El-Hateer H, Souhami L, Roberge D, Maestro RD, Leblanc R, Eldebawy E, Muanza T, Melancon D, Kavan P, Guiot MC (2009) Low-grade oligodendroglioma: an indolent but incurable disease? Clinical article. J Neurosurg 111:265–271. doi: 10.3171/2008.11.JNS08983 PubMedCrossRefGoogle Scholar
  77. 77.
    Rudoler S, Corn BW, Werner-Wasik M, Flanders A, Preston PE, Tupchong L, Curran WJ Jr (1998) Patterns of tumor progression after radiotherapy for low-grade gliomas: analysis from the computed tomography/magnetic resonance imaging era. Am J Clin Oncol 21:23–27PubMedCrossRefGoogle Scholar
  78. 78.
    Westergaard L, Gjerris F, Klinken L (1993) Prognostic parameters in benign astrocytomas. Acta Neurochir (Wien) 123:1–7CrossRefGoogle Scholar
  79. 79.
    Whitton AC, Bloom HJ (1990) Low grade glioma of the cerebral hemispheres in adults: a retrospective analysis of 88 cases. Int J Radiat Oncol Biol Phys 18:783–786PubMedCrossRefGoogle Scholar
  80. 80.
    Kaloshi G, Psimaras D, Mokhtari K, Dehais C, Houillier C, Marie Y, Laigle-Donadey F, Taillibert S, Guillevin R, Martin-Duverneuil N, Sanson M, Hoang-Xuan K, Delattre JY (2009) Supratentorial low-grade gliomas in older patients. Neurology 73:2093–2098. doi: 10.1212/WNL.0b013e3181c6781e PubMedCrossRefGoogle Scholar
  81. 81.
    Yeh SA, Ho JT, Lui CC, Huang YJ, Hsiung CY, Huang EY (2005) Treatment outcomes and prognostic factors in patients with supratentorial low-grade gliomas. Br J Radiol 78:230–235PubMedCrossRefGoogle Scholar
  82. 82.
    Iwabuchi S, Bishara S, Herbison P, Erasmus A, Samejima H (1999) Prognostic factors for supratentorial low grade astrocytomas in adults. Neurol Med Chir 39:273–279 (discussion 279–281) CrossRefGoogle Scholar
  83. 83.
    Shinoda J, Sakai N, Nakatani K, Funakoshi T (1998) Prognostic factors in supratentorial WHO grade II astrocytoma in adults. Br J Neurosurg 12:318–324PubMedCrossRefGoogle Scholar
  84. 84.
    Schuurman PR, Troost D, Verbeeten B Jr, Bosch DA (1997) 5-year survival and clinical prognostic factors in progressive supratentorial diffuse “low-grade” astrocytoma: a retrospective analysis of 46 cases. Acta Neurochir (Wien) 139:2–7CrossRefGoogle Scholar
  85. 85.
    Bahary JP, Villemure JG, Choi S, Leblanc R, Olivier A, Bertrand G, Souhami L, Tampieri D, Hazel J (1996) Low-grade pure and mixed cerebral astrocytomas treated in the CT scan era. J Neurooncol 27:173–177PubMedCrossRefGoogle Scholar
  86. 86.
    Jubelirer SJ, Rubin M, Shim C (1993) An analysis of 38 cases of low-grade cerebral astrocytoma in adults. West Va Med J 89:102–105Google Scholar
  87. 87.
    Franklin CI (1991) The treatment of low grade cerebral astrocytomas by radiotherapy in Queensland. Australas Radiol 35:68–71PubMedCrossRefGoogle Scholar
  88. 88.
    Arienti VM, Botturi A, Boiardi A, Broggi G, Collice M, Fariselli L, Zanni D, Botturi M (2001) Adult brain low-grade astrocytomas: survival after surgery and radiotherapy. Neurol Sci 22:233–238. doi: 10.1007/s100720100003 PubMedCrossRefGoogle Scholar
  89. 89.
    Kuo LT, Kuo KT, Lee MJ, Wei CC, Scaravilli F, Tsai JC, Tseng HM, Kuo MF, Tu YK (2009) Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. Int J Cancer 124:2872–2879. doi: 10.1002/ijc.24303 PubMedCrossRefGoogle Scholar
  90. 90.
    Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, Peraud A, Kreth FW (2012) IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer 118:452–460PubMedCrossRefGoogle Scholar
  91. 91.
    Bauman G, Pahapill P, Macdonald D, Fisher B, Leighton C, Cairncross G (1999) Low grade glioma: a measuring radiographic response to radiotherapy. Can J Neurol Sci 26:18–22PubMedGoogle Scholar
  92. 92.
    Kreth FW, Faist M, Warnke PC, Rossner R, Volk B, Ostertag CB (1995) Interstitial radiosurgery of low-grade gliomas. J Neurosurg 82:418–429. doi: 10.3171/jns.1995.82.3.0418 PubMedCrossRefGoogle Scholar
  93. 93.
    Kano H, Niranjan A, Khan A, Flickinger JC, Kondziolka D, Lieberman F, Lunsford LD (2009) Does radiosurgery have a role in the management of oligodendrogliomas? J Neurosurg 110:564–571. doi: 10.3171/2008.5.17582 PubMedCrossRefGoogle Scholar
  94. 94.
    Simonova G, Novotny J Jr, Liscak R (2005) Low-grade gliomas treated by fractionated gamma knife surgery. J Neurosurg 102(Suppl):19–24PubMedCrossRefGoogle Scholar
  95. 95.
    Heppner PA, Sheehan JP, Steiner LE (2005) Gamma knife surgery for low-grade gliomas. Neurosurgery 57:1132–1139 (discussion) PubMedCrossRefGoogle Scholar
  96. 96.
    Combs SE, Widmer V, Thilmann C, Hof H, Debus J, Schulz-Ertner D (2005) Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM). Cancer 104:2168–2173. doi: 10.1002/cncr.21429 PubMedCrossRefGoogle Scholar
  97. 97.
    Fitzek MM, Thornton AF, Gt Harsh, Rabinov JD, Munzenrider JE, Lev M, Ancukiewicz M, Bussiere M, Hedley-Whyte ET, Hochberg FH, Pardo FS (2001) Dose-escalation with proton/photon irradiation for Daumas-Duport lower-grade glioma: results of an institutional phase I/II trial. Int J Radiat Oncol Biol Phys 51:131–137PubMedCrossRefGoogle Scholar
  98. 98.
    Kreth FW, Faist M, Rossner R, Birg W, Volk B, Ostertag CB (1997) The risk of interstitial radiotherapy of low-grade gliomas. Radiother Oncol 43:253–260PubMedCrossRefGoogle Scholar
  99. 99.
    Pu AT, Sandler HM, Radany EH, Blaivas M, Page MA, Greenberg HS, Junck L, Ross DA (1995) Low grade gliomas: preliminary analysis of failure patterns among patients treated using 3D conformal external beam irradiation. Int J Radiat Oncol Biol Phys 31:461–466. doi: 10.1016/0360-3016(94)00400-f PubMedCrossRefGoogle Scholar
  100. 100.
    Ribba B, Kaloshi G, Peyre M, Ricard D, Calvez V, Tod M, Cajavec-Bernard B, Idbaih A, Psimaras D, Dainese L, Pallud J, Cartalat-Carel S, Delattre JY, Honnorat J, Grenier E, Ducray F (2012) A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy. Clin Cancer Res 18:5071–5080. doi: 10.1158/1078-0432.CCR-12-0084 PubMedCrossRefGoogle Scholar
  101. 101.
    Pallud J, Llitjos JF, Dhermain F, Varlet P, Dezamis E, Devaux B, Souillard-Scemama R, Sanai N, Koziak M, Page P, Schlienger M, Daumas-Duport C, Meder JF, Oppenheim C, Roux FX (2012) Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas. Neuro Oncol 14:496–505. doi: 10.1093/neuonc/nos069 PubMedCentralPubMedCrossRefGoogle Scholar
  102. 102.
    Fathi AR, Vassella E, Arnold M, Curschmann J, Reinert M, Vajtai I, Weis J, Deiana G, Mariani L (2007) Objective response to radiation therapy and long-term survival of patients with WHO grade II astrocytic gliomas with known LOH 1p/19q status. Strahlenther Onko 183:517–522. doi: 10.1007/s00066-007-1673-6 CrossRefGoogle Scholar
  103. 103.
    Hilton DA, Love S, Barber R, Ellison D, Sandeman DR (1998) Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy. Neurosurgery 42:724–729PubMedCrossRefGoogle Scholar
  104. 104.
    Singer JM (1995) Supratentorial low grade gliomas in adults. A retrospective analysis of 43 cases treated with surgery and radiotherapy. Eur J Surg Oncol 21:198–200PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Timothy C. Ryken
    • 1
  • Ian Parney
    • 2
  • John Buatti
    • 3
  • Steven N. Kalkanis
    • 4
  • Jeffrey J. Olson
    • 5
  1. 1.Department of NeurosurgeryKansas University Medical CenterKansas CityUSA
  2. 2.Department of NeurosurgeryMayo ClinicRochesterUSA
  3. 3.Department of Radiation OncologyUniversity of Iowa Hospitals & ClinicsIowa CityUSA
  4. 4.Department of NeurosurgeryHenry Ford Health SystemDetroitUSA
  5. 5.Department of NeurosurgeryEmory University School of MedicineAtlantaUSA

Personalised recommendations